JP2024544625A5 - - Google Patents
Info
- Publication number
- JP2024544625A5 JP2024544625A5 JP2024532155A JP2024532155A JP2024544625A5 JP 2024544625 A5 JP2024544625 A5 JP 2024544625A5 JP 2024532155 A JP2024532155 A JP 2024532155A JP 2024532155 A JP2024532155 A JP 2024532155A JP 2024544625 A5 JP2024544625 A5 JP 2024544625A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- alkyl
- bid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285457P | 2021-12-02 | 2021-12-02 | |
| US63/285,457 | 2021-12-02 | ||
| PCT/IB2022/061652 WO2023100134A1 (en) | 2021-12-02 | 2022-12-01 | Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024544625A JP2024544625A (ja) | 2024-12-03 |
| JP2024544625A5 true JP2024544625A5 (cg-RX-API-DMAC10.html) | 2025-11-21 |
Family
ID=84462534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532155A Pending JP2024544625A (ja) | 2021-12-02 | 2022-12-01 | がんを処置するためのcdk2阻害剤およびcdk4阻害剤を含む方法および投薬レジメン |
Country Status (12)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| EP4604961A1 (en) * | 2022-10-18 | 2025-08-27 | Pfizer Inc. | Compounds for the treatment of cancer |
| EP4719405A1 (en) * | 2023-06-02 | 2026-04-08 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| WO2025202871A1 (en) * | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
| WO2025202854A1 (en) * | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| WO2026133192A1 (en) * | 2024-12-20 | 2026-06-25 | Pfizer Inc. | Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| CN118286225A (zh) | 2018-04-26 | 2024-07-05 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
| CA3128155C (en) | 2019-01-31 | 2023-09-19 | Pfizer Inc. | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 |
-
2022
- 2022-12-01 EP EP22821653.7A patent/EP4440575A1/en active Pending
- 2022-12-01 MX MX2024006747A patent/MX2024006747A/es unknown
- 2022-12-01 KR KR1020247021935A patent/KR20240112932A/ko active Pending
- 2022-12-01 IL IL312980A patent/IL312980A/en unknown
- 2022-12-01 US US18/715,085 patent/US20250041277A1/en active Pending
- 2022-12-01 JP JP2024532155A patent/JP2024544625A/ja active Pending
- 2022-12-01 AU AU2022402512A patent/AU2022402512A1/en not_active Abandoned
- 2022-12-01 CA CA3241001A patent/CA3241001A1/en active Pending
- 2022-12-01 WO PCT/IB2022/061652 patent/WO2023100134A1/en not_active Ceased
- 2022-12-01 CN CN202280090883.2A patent/CN118647379A/zh active Pending
- 2022-12-02 TW TW111146439A patent/TWI873485B/zh active
-
2024
- 2024-06-13 ZA ZA2024/04615A patent/ZA202404615B/en unknown
-
2026
- 2026-02-20 AU AU2026201311A patent/AU2026201311A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522275A5 (cg-RX-API-DMAC10.html) | ||
| CN1332974C (zh) | 抗雌激素甾族化合物、有关的药学组合物和使用方法 | |
| JP2023541522A5 (cg-RX-API-DMAC10.html) | ||
| JP7595413B2 (ja) | 15-pgdh阻害剤とコルチコステロイドおよび/またはtnf阻害剤との組み合わせならびにその使用 | |
| US8143410B2 (en) | Kinase inhibitors | |
| US9708311B2 (en) | Benzimidazole derivatives as EP4 antagonists | |
| US8455656B2 (en) | Kinase inhibitors | |
| JP2008500988A5 (cg-RX-API-DMAC10.html) | ||
| JP2021501754A5 (cg-RX-API-DMAC10.html) | ||
| JP2008500990A5 (cg-RX-API-DMAC10.html) | ||
| JP2014528464A5 (cg-RX-API-DMAC10.html) | ||
| JP2000256194A (ja) | 核内レセプタ作動薬およびその効果増強剤 | |
| EA016887B1 (ru) | ЗАМЕЩЁННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α | |
| JP2023506787A5 (cg-RX-API-DMAC10.html) | ||
| TW201607943A (zh) | 作為ep4配體之新穎苯并咪唑衍生物 | |
| JP2014501732A (ja) | 骨癌の疼痛におけるシグマリガンドの使用 | |
| JP2009516747A5 (cg-RX-API-DMAC10.html) | ||
| JP2015517523A5 (cg-RX-API-DMAC10.html) | ||
| US10172814B2 (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
| JP2024538730A5 (cg-RX-API-DMAC10.html) | ||
| JP2002522423A (ja) | α1A作動薬としてのイミダゾール及び関連化合物 | |
| Zbieg et al. | Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer | |
| JP2025510512A5 (cg-RX-API-DMAC10.html) | ||
| Guo et al. | Estrogen Receptor α (ERα)-targeting compounds and derivatives: Recent advances in structural modification and bioactivity | |
| US10793525B2 (en) | 13-cis-RAMBA retinamides that degrade MNKs for treating cancer |